573 related articles for article (PubMed ID: 30257549)
1. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
[TBL] [Abstract][Full Text] [Related]
2. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT).
Koh KK; Nam CW; Chao TH; Liu ME; Wu CJ; Kim DS; Kim CJ; Li I; Li J; Baccara-Dinet MT; Hsiao PJ; Chiang CE
J Clin Lipidol; 2018; 12(1):162-172.e6. PubMed ID: 29153823
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
Colhoun HM; Robinson JG; Farnier M; Cariou B; Blom D; Kereiakes DJ; Lorenzato C; Pordy R; Chaudhari U
BMC Cardiovasc Disord; 2014 Sep; 14():121. PubMed ID: 25240705
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM
Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
[TBL] [Abstract][Full Text] [Related]
9. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab.
Chao TH; Hsiao PJ; Liu ME; Wu CJ; Chiang FT; Chen ZC; Chen CP; Yeh HI; Lee TH; Chiang CE
J Chin Med Assoc; 2019 Apr; 82(4):265-271. PubMed ID: 30946207
[TBL] [Abstract][Full Text] [Related]
10. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
12. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
13. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
Ginsberg HN; Tuomilehto J; Hovingh GK; Cariou B; Santos RD; Brown AS; Sanganalmath SK; Koren A; Thompson D; Raal FJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):69-76. PubMed ID: 30734207
[TBL] [Abstract][Full Text] [Related]
14. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of alirocumab versus ezetimibe in high cardiovascular risk Chinese patients with hyperlipidemia: ODYSSEY EAST Study-Chinese sub-population analysis].
Han YL; Ma YY; Su GH; Li Y; Li Y; Liu DF; Song R; Li JY
Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):593-599. PubMed ID: 32842270
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
